INTRODUCTION
There were a lot of studies and research work to find out the cause of eclampsia but the etiology is still unclear. Severe per-eclampsia and eclampsia are one of the important cause of maternal mortality around the world. The purpose of administering prophylactic dose of magnesium sulphate (MgSO 4 ) is to reduce maternal and perinatal mortality and morbidity. The routine use of magnesium sulphate (MgSO 4 ) in the management of preeclampsia started after the publication of Magpie trial 1 at 2002. So it is highly practicable to give at least initial prophylactic dose of magnesium sulphate (MgSO 4 ) to all severe pre-eclampsia to reduce maternal and perinatal mortality and morbidity before referring to higher center. 4 hourly for 24 hours) given. Both the groups were followed up and cared accordingly till discharged from the hospital. Obstetrics complication were managed accordingly all the babies of pre-eclamptic mother were managed by hospital neonatal care unit.
METHODS

This is
RESULTS
100 patients were selected in this study. The range of age all patents were 17 to 36 years. None of 50 patient patients were none had antenatal and postpartum eclampsia. 8 patents (16%) in group B developed eclampsia. Maternal mortality is nil in group A. Out of 50 patient in group B, 4 patient (4%) expired. New born babies from group A, 8 babied (16%) admitted in sick neonatal care unit in comparison to 18 babies (36%) from group B. 
